Index. Note: Page numbers of article titles are in boldface type.
|
|
- Flora Cooper
- 5 years ago
- Views:
Transcription
1 Index Note: Page numbers of article titles are in boldface type. A Adaptive therapy, for locally advanced gastroesophageal cancers, 447 Adenocarcinoma, emerging novel therapeutic agents for gastroesophageal and gastric, cancer stem cells, signal transducers and activators of transcription 3 (STAT3) inhibitors, CLDN18.2 inhibitors, fibroblast growth factor receptor 2 (FGFR2) inhibitors, AZD4547, resistance to, 533 role in trastuzumab resistance, 533 matrix metalloproteinase (MMP) inhibitors, marimastat, 541 specific MMP 9 inhibitors, gastroesophageal, targeted therapies for, epidermal growth factor receptor, ERBB2 (HER2), MET, intramucosal esophageal, and Barrett s esophagus, chemoprevention in, NSAIDs, 416 proton pump inhibitors, endoscopic surveillance of, 414 epidemiology, genetics, and natural history of, eradication of dysplasia and reduction of progression, 416 evaluation of, high-grade dysplasia and intramucosal adenocarcinoma, low-grade dysplasia, management objectives in, management of underlying GERD, 415 nondysplastic, predictors of progression, screening for, 414 Adjuvant therapy, chemoradiation for localized gastric cancer, for locally advanced gastroesophageal cancers, chemoradiation, chemotherapy, Anatomic location, of gastroesophageal cancers, impact on management, Antiangiogenic therapy, in gastroesophageal cancer, angiogenesis pathway, 500 inhibitors of VEGF axis via monoclonal antibodies, anti-vegf monoclonal antibody, Hematol Oncol Clin N Am 31 (2017) /17 hemonc.theclinics.com
2 554 Index Antiangiogenic (continued) anti-vegfr2 monoclonal antibody, locally advanced disease, 505 ongoing areas of research, combination with anti-her2 therapy, 506 combination with immune checkpoint therapy, predictive biomarkers, tyrosine kinase inhibition of VEGF axis, 504 apatinib in third-line therapy, 504 regorafenib in second/third-line therapy, 504 Apatinib, for gastroesophageal cancer therapy, 504 Archaea, in gastric microbiome, 394 Avelumab, efficacy in gastroesophageal cancer management, AZD4547, novel therapy for gastroesophageal and gastric adenocarcinomas, B Bacteria. See also Microbiome. esophageal, gastric, Barrett esophagus, and intramucosal esophageal adenocarcinoma, chemoprevention in, NSAIDs, 416 proton pump inhibitors, endoscopic surveillance of, 414 epidemiology, genetics, and natural history of, eradication of dysplasia and reduction of progression, 416 evaluation of, high-grade dysplasia and intramucosal adenocarcinoma, low-grade dysplasia, management objectives in, management of underlying GERD, 415 nondysplastic, predictors of progression, screening for, 414 Biomarkers, predictive, for gastroesophageal cancers, C Cancer stem cells, in novel therapies for gastroesophageal and gastric adenocarcinomas, Carcinogenesis, gastric, influence of gastric microbiome on, community dynamics and pathobionts, diversity of along the GI tract, archaea, 393 esophageal bacteria, fungi, gastric bacteria, viruses, epidemiologic associations with diseases, Epstein-Barr virus, 396
3 Helicobacter pylori, other, 396 evidence for microbiome shifts with prior Helicobacter pylori infection, Epstein-Barr virus, 398 Fusobacterium sp, 399 other species, 399 identification methodologies from clinical samples, computational identification, experimental approaches, 394 molecular associations and mechanisms of carcinogenesis, Helicobacter pylori tumorigenicity, Checkpoint inhibitors, evolving role in esophageal cancer management, adjuvant studies, in combination with antiangiogenic therapy, efficacy of CTLA-4 inhibitors, 491 ipilumumab or tremelimumab, 491 efficacy of PD-1/PD-L1 inhibitors, avelumab, durvalumab, 491 nivolumab, 490 pembrolizumab, localized, role of radiotherapy in, in esophageal cancer, in gastric cancer, locally advanced, management of, differences in anatomic location and histology, multimodal treatment options, options to improve current approaches, overview, 442 PD-L1 expression in, 488 predictive biomarkers to guide use of, gene signatures, 489 mononuclear inflammatory score, PD-L1/PD-L2 status, 488 rationale for investigating, chronic inflammation, 487 genomic instability, 487 high somatic burden, 487 infection, Chemoradiation, for localized esophageal cancer, definitive, neoadjuvant, for localized gastric cancer, adjuvant, neoadjuvant, for locally advanced gastroesophageal cancers, adjuvant, preoperative, Chemotherapy, for locally advanced gastroesophageal cancers, adjuvant, 445 perioperative, for metastatic gastric cancer, Index 555
4 556 Index Chemotherapy (continued) first-line chemotherapy, fluoropyrimidines, for HER2-positive disease, platinum compounds, 472 standard regimens, 475 triplet combinations with epirubicin or docetaxel, second-line chemotherapy, Claudin inhibitors, novel therapy for gastroesophageal and gastric adenocarcinomas, CLDN182 inhibitors, novel therapy for gastroesophageal and gastric adenocarcinomas, Computerized tomography (CT), for staging esophageal and gastric cancers, with positron emission tomography (PET), Cytotoxic T-lymphocyte associated-4 inhibitors, efficacy in gastroesophageal cancer management, 491 ipilumumab, 491 tremelimumab, 491 D Doxorubicin, with triplet combinations in first-line chemotherapy for metastatic gastric cancer, Durvalumab, efficacy in gastroesophageal cancer management, 491 Dysplasia, eradication of, in Barrett s esophagus, 416 high-grade, in Barrett s esophagus, low-grade, in Barrett s esophagus, E Endoscopic resection, for staging esophageal and gastric cancers, Endoscopic surveillance, of Barrett s esophagus, 414 Endoscopic ultrasound, for staging esophageal and gastric cancers, Epidermal growth factor receptor, targeted therapy for gastroesophageal adenocarcinoma, Epirubicin, with triplet combinations in first-line chemotherapy for metastatic gastric cancer, Epstein-Barr virus, epidemiologic association with gastric diseases, 396, 398 epigenetic alterations, 398 latent infection in gastric epithelial cells, 398 viral micrornas, 398 Esophageal cancers. See also Gastroesophageal cancers. intramucosal adenocarcinoma, Barrett esophagus and, chemoprevention in, NSAIDs, 416 proton pump inhibitors, endoscopic surveillance of, 414 epidemiology, genetics, and natural history of, eradication of dysplasia and reduction of progression, 416 evaluation of, high-grade dysplasia and intramucosal adenocarcinoma,
5 Index 557 low-grade dysplasia, management objectives in, management of underlying GERD, 415 nondysplastic, predictors of progression, screening for, 414 staging in, cancer of the gastroesophageal junction, CT, endoscopic ultrasound and endoscopic resection, MRI, 435 PET-CT, staging laparoscopy, 436 F Fibroblast growth factor receptor 2 (FGFR2) inhibitors, for gastroesophageal and gastric adenocarcinomas, AZD4547, resistance to, 533 role in traztuzumab resistance, 533 Fluoropyrimidine, in first-line chemotherapy for metastatic gastric cancer, Fungi, in gastric microbiome, Fusobacterium sp, epidemiologic association with gastric diseases, 399 G Gastric cancers. See also Gastroesophageal cancers. metastatic, management of, first-line chemotherapy, fluoropyrimidines, for HER2-positive disease, platinum compounds, 472 standard regimens, 475 triplet combinations with epirubicin or docetaxel, second-line chemotherapy, special situations, metastatectomy, 479 peritonectomy, 479 synchronous metastases, treatment goals, staging in, cancer of the gastroesophageal junction, CT, endoscopic ultrasound and endoscopic resection, MRI, 435 PET-CT, staging laparoscopy, 436 Gastric microbiome. See Microbiome, gastric. Gastroesophageal cancers. See also Esophageal cancers and Gastric cancers. antiangiogenic therapy in,
6 558 Index Gastroesophageal (continued ) angiogenesis pathway, 500 inhibitors of VEGF axis via monoclonal antibodies, anti-vegf monoclonal antibody, anti-vegfr2 monoclonal antibody, locally advanced disease, 505 ongoing areas of research, combination with anti-her2 therapy, 506 combination with immune checkpoint therapy, predictive biomarkers, tyrosine kinase inhibition of VEGF axis, 504 apatinib in third-line therapy, 504 regorafenib in second/third-line therapy, 504 emerging novel therapeutic agents for gastroesophageal and gastric, cancer stem cells, signal transducers and activators of transcription 3 (STAT3) inhibitors, CLDN18.2 inhibitors, fibroblast growth factor receptor 2 (FGFR2) inhibitors, AZD4547, resistance to, 533 role in trastuzumab resistance, 533 matrix metalloproteinase (MMP) inhibitors, marimastat, 541 specific MMP 9 inhibitors, evolving role of checkpoint inhibitors in, adjuvant studies, efficacy of CTLA-4 inhibitors, 491 ipilumumab or tremelimumab, 491 efficacy of PD-1/PD-L1 inhibitors, avelumab, durvalumab, 491 nivolumab, 490 pembrolizumab, localized, role of radiotherapy in, in esophageal cancer, in gastric cancer, PD-L1 expression in, 488 predictive biomarkers to guide use of, gene signatures, 489 mononuclear inflammatory score, PD-L1/PD-L2 status, 488 rationale for investigating, chronic inflammation, 487 genomic instability, 487 high somatic burden, 487 infection, future directions in improving outcomes, disease prevention, in locally advanced disease, application of novel imaging to identify response, integration of targeted therapies, 549 molecular classification of disease,
7 Index 559 gastroesophageal, targeted therapies for, epidermal growth factor receptor, ERBB2 (HER2), MET, localized, role of radiotherapy in, emerging technologies, image-guided, MRI-guided, proton therapy, in esophageal cancer, definitive chemoradiation, neoadjuvant chemoradiation, in gastric cancer, adjuvant chemoradiation, neoadjuvant chemoradiation, locally advanced, management of, differences in anatomic location and histology, multimodal treatment options, adjuvant chemoradiation, perioperative chemotherapy, preoperative chemoradiation, options to improve current approaches, adaptive therapy based on early response prediction, 446 optimization by targeted therapy, 447 overview, 442 Gastroesophageal junction, staging of cancer of, 428 Gastroesophageal reflux disease (GERD), management of, in Barrett s esophagus, 415 H Helicobacter pylori, disease prevention and improved outcomes with gastroesophageal cancers, epidemiologic association with gastric diseases, evidence for prolonged microbiome shifts associated with prior infection with, mechanisms of tumorigenicity, Histology, of gastroesophageal cancers, impact on management, Human epidermal growth factor 2 (HER2), anti-her2 therapy in combination with antiangiogenic therapy, 506 HER2-positive metastatic gastric cancer, first-line chemotherapy for, Human papillomavirus (HPV), risk factor for Barrett s esophagus and esophageal adenocarcinoma, 410 I Immune checkpoint therapy. See Checkpoint inhibitors. Immunotherapy. See Antiangiogenic therapy. Ipilimumab, efficacy in gastroesophageal cancer management, 491 L Laparoscopy, staging, for esophageal and gastric cancers, 437 Locally advance gastroesophageal cancers antiangiogenic therapy in, 505
8 560 Index Locally (continued) future directions in improving outcomes of, integration of targeted therapies, 549 novel imaging to identify response, management of, differences in anatomic location and histology, multimodal treatment options, adjuvant chemoradiation, perioperative chemotherapy, preoperative chemoradiation, options to improve current approaches, adaptive therapy based on early response prediction, 446 optimization by targeted therapy, 447 overview, 442 M Magnetic resonance imaging (MRI), MRI-guided radiation therapy for esophageal and gastric cancers, for staging esophageal and gastric cancers, 435 Marimastat, for gastroesophageal and gastric adenocarcinomas, 541 Matrix metalloproteinase (MMP) inhibitors, for gastroesophageal and gastric adenocarcinomas, marimastat, 541 specific MMP 9 inhibitors, MET protooncogene, in targeted therapies for gastroesophageal adenocarcinoma, Metastatectomy, in management of metastatic gastric cancer, 479 Metastatic cancer, gastric, management of, first-line chemotherapy, fluoropyrimidines, for HER2-positive disease, platinum compounds, 472 standard regimens, triple combinations with epirubicin or docetaxel, second-line chemotherapy, special situations, metastatectomy, 479 peritonectomy, 479 synchronous metastases, treatment goals, Microbiome, gastric, influence on gastric carcinogenesis, community dynamics and pathobionts, diversity of along the GI tract, archaea, 393 esophageal bacteria, fungi, gastric bacteria, viruses, epidemiologic associations with diseases, Epstein-Barr virus, 396
9 Index 561 Helicobacter pylori, other, 396 evidence for microbiome shifts with prior Helicobacter pylori infection, Epstein-Barr virus, 398 Fusobacterium sp, 399 other species, 399 identification methodologies from clinical samples, computational identification, experimental approaches, 394 molecular associations and mechanisms of carcinogenesis, Helicobacter pylori tumorigenicity, Molecular profiling, in improving outcomes with gastroesophageal cancers, MRI-guided radiation therapy, for localized esophageal and gastric cancers, Multimodal therapy, of locally advanced gastroesophageal cancers, N Napabucasin (BBI-608), novel therapy for gastroesophageal and gastric adenocarcinomas, with weekly paclitaxel, Neoadjuvant therapy, chemoradiation for localized esophageal cancer, chemoradiation for localized gastric cancer, chemoradiation for locally advanced gastroesophageal cancers, Nivolumab, efficacy in gastroesophageal cancer management, 490 Nonsteroidal antiinflammatory drugs (NSAIDs), for Barrett s esophagus, 416 O Outcomes, with gastroesophageal cancer, future directions in improving, disease prevention, in locally advanced disease, application of novel imaging to identify response, integration of targeted therapies, 549 molecular classification of disease, P Paclitaxel, weekly, with napabucasin (BBI-608) for gastroesophageal and gastric adenocarcinomas, Pembrolizumab, efficacy in gastroesophageal cancer management, Peritonectomy, in management of metastatic gastric cancer, 479 Platinum compounds, in first-line chemotherapy for metastatic gastric cancer, 472 Positron emission tomography (PET), with CT for staging esophageal and gastric cancers, Prevention, in improving outcomes with gastroesophageal cancers, Programmed death ligand 1 (PD-L1), efficacy of PD-1/PD-L1 inhibitors in gastroesophageal cancer, avelumab, durvalumab, 491 nivolumab, 490 pembrolizumab, expression in gastroesophageal cancer, 488
10 562 Index Programmed (continued) PD-L1/PD-L2 status as predictive biomarker in gastroesophageal cancer, 488 Proton pump inhibitors, for Barrett s esophagus, Proton therapy, for localized esophageal and gastric cancers, R Radiotherapy, role in localized esophageal and gastric cancer, emerging technologies, image-guided, MRI-guided, proton therapy, in esophageal cancer, definitive chemoradiation, neoadjuvant chemoradiation, in gastric cancer, adjuvant chemoradiation, neoadjuvant chemoradiation, Regorafenib, for gastroesophageal cancer therapy, 504 Resection, endoscopic, for staging esophageal and gastric cancers, S Signal transducers and activators of transcription 3 (STAT3) inhibitors, in novel therapies for gastroesophageal and gastric adenocarcinomas, combination of BBI-608 and weekly paclitaxel, napabucasin (BBI-608), 538 OPB-31121, 538 OPB-51602, 538 Staging, in esophageal and gastric cancers, cancer of the gastroesophageal junction, CT, endoscopic ultrasound and endoscopic resection, MRI, 435 PET-CT, staging laparoscopy, 436 Stem cells, cancer, in novel therapies for gastroesophageal and gastric adenocarcinomas, Surveillance, endoscopic, of Barrett s esophagus, 414 Synchronous metastases, of gastric cancer, management of, T Targeted therapies, for gastroesophageal adenocarcinoma, epidermal growth factor receptor, ERBB2 (HER2), MET, for locally advanced gastroesophageal cancers, 447 role in improving outcomes for gastroesophageal cancer, Trastuzumab, in targeted therapy of gastroesophageal adenocarcinoma, role of FGFR in resistance to, 533
11 Index 563 Tremelimumab, efficacy in gastroesophageal cancer management, 491 Triplet combinations, in first-line chemotherapy for metastatic gastric cancer, Tyrosine kinase inhibition, of VEGF axis, 504 apatinib in third-line therapy, 504 regorafenib in second/third-line therapy, 504 U Ultrasound, endoscopic, for staging esophageal and gastric cancers, Upper gastrointestinal malignancies, antiangiogenic therapy in, Barrett esophagus and intramucosal esophageal adenocarcinoma, checkpoint inhibitors role in, emerging novel therapeutic agents, future directions in improving outcomes of, gastric microbiome and gastric carcinogenesis, locally advanced gastroesophageal cancer, metastatic gastric cancer, radiotherapy for localized esophageal and gastric cancer, staging in esophageal and gastric cancers, targeted therapies for adenocarcinoma, V Vascular endothelial growth factor (VEGF) axis, inhibition of via monoclonal antibodies, anti-vegf monoclonal antibody, anti-vegfr2 monoclonal antibody, Viruses, in gastric microbiome,
B Breast cancer, managing risk of lobular, in hereditary diffuse gastric cancer, 51
Index Note: Page numbers of article titles are in boldface type. A Adenocarcinoma, gastric. See also Gastric cancer. D2 nodal dissection for 57 70 Adjuvant therapy, for gastric cancer, impact of D2 dissection
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationNOVITA IN TEMA DI CARCINOMA GASTRICO ROSA BERENATO
NOVITA IN TEMA DI CARCINOMA GASTRICO ROSA BERENATO ONCOLOGIA MEDICA 1 FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI MILANO PROGRESS AGAINST METASTATIC GC OS in first-line palliative setting Little progress
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationCa Cardias e Stomaco: le diversita e le terapie
XXII Riunione Nazionale I.T.M.O. Ca Cardias e Stomaco: le diversita e le terapie Maria Di Bartolomeo s.s. Oncologia Medica Gastroenterologica Fondazione IRCCS Istituto Nazionale Tumori Milano OUTLINE History
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationCyramza. Cyramza (ramucirumab) Description. Section: Prescription Drugs Effective Date: October 1, 2014
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cyramza Page: 1 of 5 Last Review Date: September 12, 2014 Cyramza Description Cyramza (ramucirumab)
More informationGastric and Colon Cancer. Dr. Andres Wiernik 2017
Gastric and Colon Cancer Dr. Andres Wiernik 2017 GASTRIC CANCER Gastric Cancer Classification Epidemiology General principles of Management 25% GE Junction Gastric Cancer 75% Gastric Cancer Epidemiology
More informationEsophageal Cancer. What is esophageal cancer?
Scan for mobile link. Esophageal Cancer Esophageal cancer occurs when cancer cells develop in the esophagus. The two main types are squamous cell carcinoma and adenocarcinoma. Esophageal cancer may not
More informationCombination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy
Combination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy Dr. David B. Page Providence Portland Medical Center Earle A. Chiles Research Institute Funding & Disclosures
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationCyramza. Cyramza (ramucirumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.44 Subject: Cyramza Page: 1 of 6 Last Review Date: September 15, 2017 Cyramza Description Cyramza
More informationCyramza. Cyramza (ramucirumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.44 Subject: Cyramza Page: 1 of 6 Last Review Date: June 24, 2016 Cyramza Description Cyramza (ramucirumab)
More informationNasopharyngeal Cancer/Multimodality Treatment
Nasopharyngeal Cancer/Multimodality Treatment PANAGIOTIS KATSAOUNIS Medical Oncologist IASO GENERAL HOSPITAL Athens, 22/10/2016 1 st Hellenic Multidisciplinary Conference on Head and Neck Cancer INTRODUCTION
More informationGASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS. HLC174A October Usha Nagavarapu Project Analyst
GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS HLC174A October 2015 Usha Nagavarapu Project Analyst ISBN: 1-62296-167-6 BCC Research 49 Walnut Park, Building 2 Wellesley,
More informationAdvances in Chemotherapy for Non-Small Cell Lung Cancer
Advances in Chemotherapy for Non-Small Cell Lung Cancer Evan W. Alley, MD, PhD Clinical Associate Professor Abramson Cancer Center at Penn Presbyterian Lung Cancer: Overview Second most common cancer in
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
More informationEsophageal cancer. What is esophageal cancer? Esophageal cancer is a disease in which malignant (cancer) cells form in the tissues of the esophagus.
Esophageal Cancer Esophageal cancer What is esophageal cancer? What are risk factors? Signs and symptoms Tests for esophageal cancer Stages of esophageal cancer Treatment options What is esophageal cancer?
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationMy name is Dr. David Ilson, Professor of Medicine at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center in New York, New York.
Welcome to this CME/CE-certified activity entitled, Integrating the Latest Advances Into Clinical Experience: Data and Expert Insights From the 2016 Meeting on Gastrointestinal Cancers in San Francisco.
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationIndex. neurosurgery.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A A Complimentary Trial of an Immunotherapy Vaccine Against Tumor-specific EGFRvIII (ACTIVATE), 90 91 Active immunotherapy, 5 8, 96. See
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, for early-stage triple-negative breast cancer, 740 742 in older early-stage breast cancer patients, 790 795 anti-her2-directed
More informationCancer diagnosis and treatments- brief overview of the changing paradigm.
Cancer diagnosis and treatments- brief overview of the changing paradigm. Pranshu Bansal MD New Mexico Cancer Center Identifying cancer in clinic Most common cancers are lung, breast, colon, prostate and
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal surgery prior as factor in laparoscopic colorectal surgery, 554 555 Abscess(es) CRC presenting as, 539 540 Adenocarcinoma of
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
More informationThe role of immune checkpoint inhibitors in non-small cell lung cancer
Review Article Page 1 of 9 The role of immune checkpoint inhibitors in non-small cell lung cancer Tiffany L. George 1, Erin M. Bertino 2 1 Divisions of Hematology and Medical Oncology, 2 Division of Medical
More informationMEDICAL PRIOR AUTHORIZATION
MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
More informationAdvancing Diagnosis and Treatment for Gastric Cancer
Advancing Diagnosis and Treatment for Gastric Cancer The Gastric Cancer Care Program of NewYork-Presbyterian/Columbia University Medical Center provides a comprehensive strategy of early detection, multidisciplinary
More informationTreatment of gastrointestinal cancer. General considerations International guidelines
Treatment of gastrointestinal cancer General considerations International guidelines Therapeutical options Chemotherapy Moleculary targeted therapy Irradiation Immunotherapy Radiological intervention Oncosurgery
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationPaediatric strategy forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients
22 August 2018 EMA/242738/2018 Paediatric strategy forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients 5-6 September 2018 30 Churchill
More informationRadiation Therapy and Immunotherapy: New Frontiers
Radiation Therapy and Immunotherapy: New Frontiers Nevada Oncology Society Fall Meeting November 16 th, 2017 Anshu K. Jain, MD Radiation Oncologist, Ashland Bellefonte Cancer Center Assistant Clinical
More informationResectable locally advanced oesophagogastric cancer
Resectable locally advanced oesophagogastric cancer Clinical Case Discussion Florian Lordick University Cancer Center Leipzig University Clinic Leipzig Leipzig, Germany esmo.org DISCLOSURES Honoraria for
More informationUpdates and best practices in the management of gastric cancer
Updates and best practices in the management of gastric cancer Olatunji B. Alese, MD Gastrointestinal Oncology, Winship Cancer Institute of Emory University July 28, 2017 1 Incidence 3rd leading cause
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adherence, to bismuth quadruple therapy, 543 546 Adjuvant therapy, probiotics as, 567 569 Age factors, in gastric cancer, 611 612, 616 AID protein,
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationCurrent standards of care in gastric cancer
Current standards of care in gastric cancer Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be Outline Resectable gastric cancer: the role of neoadjuvant and adjuvant
More informationOverall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer
Original Article Overall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer Faisal A. Siddiqui 1, Katelyn M. Atkins 2, Brian S. Diggs 3, Charles R. Thomas Jr 1,
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab
Medical Manual Approved Revised: Do Not Implement until 6/30/2019 Nivolumab NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB
More informationThe promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1
Review Article The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1 Zhaohui Jin 1, Harry H. Yoon 2 1 Division of Hematology, Oncology and Bone & Marrow Transplantation,
More informationGetting to the Bottom of Treatment: An Update in the Management of Esophagogastric Cancers
Getting to the Bottom of Treatment: An Update in the Management of Esophagogastric Cancers Disclosures None Cindy L. O Bryant, PharmD, BCOP, FCCP, FHOPA Professor, University of Colorado Skaggs School
More informationMedicina Personalizada de Precisión en el Abordaje del Cáncer Gástrico. Dra Desamparados Roda Pérez Hospital Clínico de Valencia Incliva, CIBERONC
Medicina Personalizada de Precisión en el Abordaje del Cáncer Gástrico Dra Desamparados Roda Pérez Hospital Clínico de Valencia Incliva, CIBERONC Gastric cancer Epidemiology Gastric cancer is an important
More informationIMMUNOTHERAPY FOR LUNG CANCER
IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Lung Cancer Basics... 2 Immunotherapy... 3 FDA Approved Immunotherapies...
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
More informationEsophageal cancer: Biology, natural history, staging and therapeutic options
EGEUS 2nd Meeting Esophageal cancer: Biology, natural history, staging and therapeutic options Michael Bau Mortensen MD, Ph.D. Associate Professor of Surgery Centre for Surgical Ultrasound, Upper GI Section,
More informationCase Scenario year-old white male presented to personal physician with dyspepsia with reflux.
Case Scenario 1 57-year-old white male presented to personal physician with dyspepsia with reflux. 7/12 EGD: In the gastroesophageal junction we found an exophytic tumor. The tumor occupies approximately
More informationPD-L1 and Immunotherapy of GI cancers: What do you need to know
None. PD-L1 and Immunotherapy of GI cancers: What do you need to know Rondell P. Graham September 3, 2017 2017 MFMER slide-2 Disclosure No conflicts of interest to disclose 2017 MFMER slide-3 Objectives
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationWHO BENEFITS FROM ADJUVANT CHEMOTHERAPY RADIATION CHEMORADIATION? Dr. Paul Gardiner April 23, 2001 Discipline of Surgery Grand Rounds
WHO BENEFITS FROM ADJUVANT CHEMOTHERAPY RADIATION CHEMORADIATION? Dr. Paul Gardiner April 23, 2001 Discipline of Surgery Grand Rounds LUNG Dr. Greenland ESOPHAGUS Dr. Gardiner ESOPHAGEAL CANCER 1200 new
More informationEGFR Antibody. Necitumumab, LY , IMC-11F8. Drug Discovery Platform: Cancer Cell Signaling
EGFR Antibody Necitumumab, LY3012211, IMC-11F8 Derived from Yarden Y and Shilo BZ 1 ; Schneider MR and Wolf E. 2 Drug Discovery Platform: Cancer Cell Signaling A Single-Arm, Multicenter, Open-Label, Phase
More informationChemotherapy Treatment Algorithms for Urology Cancer
Chemotherapy Treatment Algorithms for Urology Cancer Chemoradiation for bladder cancer; Chemotherapy algorithm for non TCC bladder cancer Squamous cell carcinoma; Chemotherapy Algorithm for Non Transitional
More informationObjectives. Briefly summarize the current state of colorectal cancer
Disclaimer I do not have any financial conflicts to disclose. I will not be promoting any service or product. This presentation is not meant to offer medical advice and is not intended to establish a standard
More informationDisclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Herceptin) Reference Number: ERX.SPA.42 Effective Date: 07.01.16 Last Review Date: 05/17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the
More informationA Giant Leap in the Treatment Options for Advanced Bladder Cancer
A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer
More informationClinical Policy: Cetuximab (Erbitux) Reference Number: PA.CP.PHAR.317
Clinical Policy: (Erbitux) Reference Number: PA.CP.PHAR.317 Effective Date: 01/18 Last Review Date: 11/17 Coding Implications Revision Log Description The intent of the criteria is to ensure that patients
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationImmunotherapy for Upper GI Cancers
Immunotherapy for Upper GI Cancers Esophageal Adenocarcinoma GE Junction Adeno Gastric Carcinoma Ahmed Zakari MD Medical Director of GI Cancer Program, Florida Hospital Cancer Institute Associate Professor
More informationNew Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here
New Oncology Drugs: A PowerPoint Brief Primer Cover Title Nadeem Ikhlaque, M.D 05.19.2017 Subtitle Would Go Here Learning Objectives List novel chemotherapies and the indications of these newer agents
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous)
Nivolumab (Intravenous) NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3734-XX Opdivo 240
More informationBeyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers
Review Article Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers Jimmy Hwang Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC 28204,
More informationImmunotherapy and Targeted Therapies: The new face of cancer treatment
Immunotherapy and Targeted Therapies: The new face of cancer treatment Abdulazeez Salawu MBBS, MSc, PhD, MRCP Academic Clinical Lecturer Weston Park Hospital, Sheffield Novel Systemic Anti-cancer Therapies
More informationVEGF Receptor-2 Antagonist
VEGF Receptor-2 Antagonist Ramucirumab, LY3009806, IMC-1121B Derived from Adams RH and Alitalo K 1 ; Hicklin DJ and Ellis LM. 2 Drug Discovery Platform: Cancer Angiogenesis and Tumor Microenvironment RAINFALL:
More informationESOPHAGEAL CANCER AND GERD. Prof Salman Guraya FRCS, Masters MedEd
ESOPHAGEAL CANCER AND GERD Prof Salman Guraya FRCS, Masters MedEd Learning objectives Esophagus anatomy and physiology Esophageal cancer Causes, presentations of esophageal cancer Diagnosis and management
More informationIMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA
IMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA Kathleen Mahoney, M.D., Ph.D. Instructor of Medicine, Harvard Medical School Attending, Beth Israel Deaconess
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationHighlights STOMACH CANCER
UPDATES and NEWS from the Gastrointestinal Cancers Symposium in San Francisco Roma, 10-11 Febbraio 2017 Highlights STOMACH CANCER Lorenzo Fornaro, MD Unit of Medical Oncology 2 Azienda Ospedaliero-Universitaria
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablation. See specific types, e.g., Thermal ablation Achalasia, 53 75 described, 53 features of, 53 management of past options, 54 POEM
More informationOverview of Boehringer Ingelheim in Oncology
Overview of Boehringer Ingelheim in Oncology 2017 Conversations in Oncology in Shanghai, China Victoria Zazulina, MD BI Symposium Boehringer Ingelheim (BI) in Brief Family-owned global corporation Founded
More informationTargeted therapy in gastroesophageal cancers: past, present and future
Gastroenterology Report, 3(4), 2015, 316 329 doi: 10.1093/gastro/gov052 Advance Access Publication Date: 27 October 2015 Review REVIEW Targeted therapy in gastroesophageal cancers: past, present and future
More informationAppendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer
Appendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer Locoregional (N stage) disease was redefined in the seventh edition of the AJCC Cancer Staging Manual as any periesophageal lymph
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationTowards a more personalized approach in the treatment of esophageal cancer focusing on predictive factors in response to chemoradiation Wang, Da
University of Groningen Towards a more personalized approach in the treatment of esophageal cancer focusing on predictive factors in response to chemoradiation Wang, Da IMPORTANT NOTE: You are advised
More informationIndex. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 14 (2005) 433 439 Index Note: Page numbers of article titles are in boldface type. A Abdominosacral resection, of recurrent rectal cancer, 202 215 Ablative techniques, image-guided,
More informationACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus
ACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus Nicholas J. Shaheen, MD, MPH, FACG 1, Gary W. Falk, MD, MS, FACG 2, Prasad G. Iyer, MD, MSc, FACG 3 and Lauren Gerson, MD, MSc, FACG
More informationFecal incontinence causes 196 epidemiology 8 treatment 196
Subject Index Achalasia course 93 differential diagnosis 93 esophageal dysphagia 92 95 etiology 92, 93 treatment 93 95 work-up 93 Aminosalicylates, pharmacokinetics and aging effects 36 Antibiotics diarrhea
More informationIntended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic
Intended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic cancer Section AA Cancer Centre Referrals In the absence of metastatic
More informationNeoadjuvant Treatment for Locally Invasive Esophageal Cancer
World J Surg (2017) 41:1719 1725 DOI 10.1007/s00268-017-3959-x SURGICAL SYMPOSIUM CONTRIBUTION Neoadjuvant Treatment for Locally Invasive Esophageal Cancer Wade T. Iams 1 Victoria M. Villaflor 1 Published
More informationImmune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group
Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial
More informationInternational Course on Theranostics and Molecular Radiotherapy ImmunoPET in Breast Cancer
International Course on Theranostics and Molecular Radiotherapy ImmunoPET in Breast Cancer Geraldine Gebhart Jules Bordet Institute 5/10/2017 PLAN OF THE TALK Increasing role of antibodies in anti-cancer
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationESMO 13th World Congress on Gastrointestinal Cancer
ESMO 13th World Congress on Gastrointestinal Cancer 22-25 June, 2011 Barcelona, Spain INTRODUCTION The ESMO World Congress on Gastrointestinal Cancer took place in Barcelona from the 22nd until the 25th
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationWhich Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy
Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Joseph Chao, M.D. Assistant Clinical Professor Department of Medical Oncology & Therapeutics
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationImaging in gastric cancer
Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.
More informationCurrent therapeutic landscape for advanced gastroesophageal cancers
Review Article Page 1 of 19 Current therapeutic landscape for advanced gastroesophageal cancers Anthony Lopez 1,2, Kazuto Harada 1, Dilsa Mizrak Kaya 1, Jaffer A. Ajani 1 1 Department of Gastrointestinal
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationNasopharyngeal Cancer:Role of Chemotherapy
Nasopharyngeal Cancer:Role of Chemotherapy PANAGIOTIS KATSAOUNIS Medical Oncologist IASO GENERAL HOSPITAL Athens, 16/9/2017 2 nd Hellenic Multidisciplinary Conference on Head and Neck Cancer INTRODUCTION
More informationConflicts of Interest GI Malignancies: An Update on Current Treatment Options
Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of
More informationEORTC LUNG CANCER GROUP GROUP MEETING
Sunday 7 th October 2018 Time slot Topic / Title of presentation Chair 9.00 11.00 Board meeting 11.00 11.30 Arrivals & Welcome coffee 11.30 11.50 Welcome & Introduction New Board,, Membership status, Calendar
More informationNew Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain
New Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain PHC 2018 - www.aphc.info EASL-EORTC Guidelines EASL EORTC Guidelines. J Hepatol. 2012;56:908-43. Systemic
More information